Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | F9 | P00740 | 1/20 | 0.45 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HCN1 | O60741 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21652015 | 0.92 | CHRM5 (0.53) | CHRM5CHRM3CHRM1F9HCN4 | |
| SCHEMBL20158742 | 0.83 | HCN1 (0.49) | F9HCN4HPGDPOLBHCN1 | |
| SCHEMBL20205892 | 0.81 | MT-CO2 (0.46) | CHRM5CHRM3CHRM1F9CCR3 | |
| SCHEMBL20158868 | 0.81 | CCR3 (0.42) | HPGDCCR3RETP2RX7 | |
| SCHEMBL20069742 | 0.80 | KMT2A (0.54) | F9HCN4HPGDPOLBHCN1 | |
| SCHEMBL20069745 | 0.80 | P2RX7 (0.46) | F9HCN4POLBMAPTKMT2A | |
| SCHEMBL25504736 | 0.77 | MEN1 (0.48) | MAPTKMT2AALDH1A1 | |
| SCHEMBL20147551 | 0.77 | P2RX7 (0.47) | F9HCN4POLBMAPTKMT2A | |
| SCHEMBL21652028 | 0.75 | CHRM5 (0.52) | CHRM5CHRM3CHRM1HCN4HPGD | |
| SCHEMBL20158434 | 0.75 | BCAT2 (0.47) | HCN4HCN1CCR3RETP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CHRM5 2607/4885CHRM3 2379/4885CHRM1 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.